---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-076627"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2026-06-23T11:10:57+00:00"
generated_at: "2026-06-23T11:15:10.928966+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Armata Pharma receives $2.5M additional DoD funding for AP-SA02 Phase 3 readiness

## Summary
- Received $2.5M additional non-dilutive funding from U.S. DoD; total DoD award now $28.7M for AP-SA02 development.
- Funding supports Phase 3 readiness of AP-SA02, a bacteriophage therapy for complicated Staphylococcus aureus bacteremia.
- Company plans to initiate Phase 3 superiority study of AP-SA02 in H2 2026.
- DoD funding provided via MTEC and managed by NMRC/NAMD; non-dilutive nature preserves shareholder value.

## SEC filing metadata
- accession: 0001104659-26-076627
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2026-06-23T11:10:57+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000110465926076627/0001104659-26-076627-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000110465926076627/tm2618503d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-076627
- JSON: https://secwatch.observer/filing/0001104659-26-076627.json
- Plain text: https://secwatch.observer/filing/0001104659-26-076627.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.